Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.
Journal article
Zabkiewicz J. et al, (2020), Br J Haematol
Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia.
Journal article
Linch DC. et al, (2020), Br J Haematol, 188, 852 - 859
Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Journal article
Dillon R. et al, (2020), Blood, 135, 680 - 688
The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia.
Journal article
Linch DC. et al, (2020), Br J Haematol
Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future.
Journal article
Hills RK., (2020), Br J Haematol, 188, 29 - 35
Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?
Journal article
Burnett AK. et al, (2020), Br J Haematol, 188, 86 - 100
Increased frequency of CD4+ PD-1+ HLA-DR+ T cells is associated with disease progression in CLL.
Journal article
Elston L. et al, (2019), Br J Haematol
Cohesin-dependent regulation of gene expression during differentiation is lost in Cohesin-mutated myeloid malignancies.
Journal article
Sasca D. et al, (2019), Blood
Mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Conference paper
Eiring AM. et al, (2019), CANCER RESEARCH, 79
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Journal article
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2019), Lancet, 393, 1440 - 1452
Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.
Journal article
Marquis M. et al, (2019), Blood Cancer J, 9
Real world data and the art of maintenance therapy.
Other
Hills RK., (2019), Br J Haematol, 184, 493 - 494
Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials
Conference paper
Hills RK. et al, (2018), BLOOD, 132
Results of a Phase 2 Trial of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML) - the UK Monocle Study
Conference paper
Knapper S. et al, (2018), BLOOD, 132
Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis
Conference paper
Dillon R. et al, (2018), BLOOD, 132
Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial
Journal article
Russell N. et al, (2018), Blood, 132, 1452 - 1454
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.
Journal article
Marquis M. et al, (2018), Blood Cancer J, 8
The addition of the mTORr inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial
Journal article
Burnett AK. et al, (2018), Haematologica
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
Journal article
Burnett AK. et al, (2018), Leukemia
Potential benefit of higher dose daunorubicin in patients harbouring a FLT3-ITD mutation: Updated results of the AML17 trial
Journal article
Russell NH. et al, (2018), British Journal of Haematology, 173, 9 - 9